Skip to main content

Advertisement

Table 4 Ocular toxicities

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Patient ID AE (Preferred term) Study day of onset Duration (Days) Severity Relation to SGN-40
029-0010 Eye pain 1 4 Grade 1 Possibly
Eye pain 5 3 Grade 1 Possibly
Eye pain 8 4 Grade 1 Possibly
029-0011 Eye irritation 1 1 Grade 1 Possibly
Vision blurred 8 1 Grade 1 Possibly
044-0001 Conjunctivitis 5 14 Grade 2 Probably
Eye pain 11 11 Grade 2 Possibly
Eye infection 16 4 Grade 2 Unlikely
Orbital cellulitis (SAE) 18 4 Grade 3 Possibly
059-0001 Dry eye 16 8 Grade 2 Possibly
066-0010 Conjunctival irritation 16 22 Grade 1 Possibly
Eye pain 37 36 Grade 1 Possibly
066-0011 Conjunctival hyperaemia 4 11 Grade 2 Possibly
066-0005 Conjunctival hyperaemia 1 56 Grade 1 Unrelated
005-0002 Conjunctival hemorrhage 17 1 Grade 3 Unrelated